Characteristics and Results of Patients Treated by Therapeutic Intensification

Characteristics and Results of Patients Treated by Therapeutic Intensification Followed by Autograft of Peripheral Stem Cells and Admitted to Intensive Care and Intensive Care: Single-center Retrospective Analysis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06894381

Acronym

AutoREA

Enrollment

Registered

2025-03-25

Start date

2024-01-20

Completion date

2025-12-20

Last updated

2025-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Hemopathy

Keywords

Malignant hemopathy, allogeneic, stem cell, transplantation, chemotherapy

Brief summary

Many studies have focused on patients treated with allogeneic peripheral stem cell transplantation; few studies have until now been carried out to describe the characteristics and results of autografted patients and to attempt to determine possible prognostic factors. However, it is estimated that nearly 5% of autograft patients require MIR care. The investigators therefore wish to conduct a retrospective study including patients treated by therapeutic intensification followed by autograft of hematopoietic stem cells and admitted to the MIR department of the Hautepierre hospital of the University Hospitals of Strasbourg (HUS) within thirty days following initiation of chemotherapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Adult patient (≥18 years old) * Gender indifferent * Admitted to the Intensive Care Unit within thirty days following therapeutic intensification and autograft of peripheral stem cells for the treatment of a hematologic malignancy between 01/01/2013 and 12/31/2022

Exclusion criteria

\- Subject having expressed his opposition to the reuse of his data for scientific research purposes

Design outcomes

Primary

Measure	Time frame
Retrospective description of the clinical and biological characteristics of patients having therapeutic intensification and autograft of peripheral stem cells for the treatment of hematological malignancy	Thirty days following therapeutic intensification and autograft of peripheral stem cells in treatment of a malignant hematological disease.

Countries

France

Contacts

Primary ContactVincent CASTELAIN, MD, PhD

vincent.castelain@chru-strasbourg.fr33.3.88.12.79.15

Outcome results